Applied Pharmaceutical Chemistry 2025
APC 2025 Venue - AstraZeneca
35 Gatehouse Dr., Waltham, MA 02451
Thursday, April 10, 2025
Confirmed speakers for APC 2025
![]() |
Plenary Lecture: Ming Xian, PhD Jesse H. Metcalf Professor of Chemistry at Brown University Chemical Tools for Regulating Reactive Sulfur Species in Redox Biology |
![]() |
Plenary Lecture: Joshua Kritzer, PhD Professor, Director of Graduate Studies, Department of Chemistry at Tufts University Chemical Biology Tools for Measuring Intracellular Drug Delivery |
![]() |
Kevin Filipski, PhD Associate Research Fellow @ Pfizer The First BDK Inhibitor/Degrader Clinical Candidate, PF-07328948, as a Treatment of Heart Failure
|
![]() |
Martin Himmelbauer, PhD Principal Scientist @ Biogen Discovery of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK-Inhibitor for the Treatment of MS
|
![]() |
Karthik Iyer, PhD Director, Medicinal Chemistry @ Arrakis Therapeutics Drugging MYC mRNA with Small Molecules
|
![]() |
Colin (Jianglin) Liang, PhD Senior Director, Process Chemistry, CMC @ Tango Therapeutics Development of a Commercial-Ready Process for TNG908, a Potent, Selective, and Brain Penetrant MTA-Cooperative PRMT5 Inhibitor |
![]() |
Abba Leffler, PhD Senior Principal Scientists, Drug Discovery Group @ Schrodinger Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations
|
![]() |
Teresa Mako, PhD Senior Scientist, Medicinal Chemistry @ Orum Therapeutics PROTAb Platform: An Innovative Universal Linker for DACs with CRBN-Based Degraders |
![]() |
Mark Mantell, PhD Scientist @ GSK DNA Encoded Libraries – Drug Discovery through DEL screening and the Application of On-DNA Binder Confirmation
|
![]() |
Brandon Vara, PhD Associate Principal Scientist, Discovery Chemistry @ Merck Research Laboratories Discovery of a Novel Aryl Ether Small Molecule Inhibitor of the YAP1-TEAD Transcriptional Complex |
![]() |
Daniel Smaltz, PhD Associate Research Fellow, Medicinal Chemistry, @ Pfizer Discovery and Optimization of a Series of MALT1 Inhibitors Using Structure-Based Drug Design and Parallel Medicinal Chemistry |
Join our LinkedIn Group